ABOUT PROGENERON

Progeneron is a first-of-its-kind multi-action product created to mitigate the progression and symptoms associated with Palmar Fibromatosis (Dupuytren's contracture). It has been the subject of a 90-day IRB safety study and a 180-day IRB efficacy study in which 95% of the population showed no signs of disease progression. Progeneron is owned and operated by Eresina, LLC (EresinaLabs.com), a biotech research and development company specializing in fibrotic tissue disorders and diseases. Clinical data, including studies, is available to physicians via our Progeneron Physician Portal and to the public, where applicable, via the Scharp Lacy Research Institute, a 501(c)(3) nonprofit institution focusing on Diabetes, Stem Cell, and Dupuytren's research.
ABOUT DR. DAVID SCHARP, MD

Dr. David Scharp, MD, created Progeneron. For 30 years, he trained, taught, and worked at Washington University School of Medicine, St. Louis, MO, as a Professor of Surgery and researcher in islet transplantation. Dr. Scharp has been awarded numerous NIH and JDRF research grants, has produced over 200 peer-reviewed publications, and has been cited over 9000 times. Dr. Scharp has Dupuytren's Contracture and is researching and developing clinical products at Eresina Labs and the Scharp Lacy Research Institute, a nonprofit 501(c)(3) focusing on Diabetes, Stem Cell, and Dupuytren's Disease.

KEEP READING
HANDCREAM
SHOP NOW